Hepatitis B: Progress in the Last Decade

Anna S. F. Lok

doi:10.1055/s-2003-37592

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2003; 23(1): 001-004
DOI: 10.1055/s-2003-37592

FOREWORD

Hepatitis B: Progress in the Last Decade

Anna S.F. Lok

Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, Michigan

Abstract

Volltext

Referenzen

REFERENCES

1 Blumberg B S, Alter H J. A "new" antigen in leukemia sera. JAMA . 1965; 191 101-106
2 London W T, Sutnick A I, Blumberg B S. Australia antigen and acute viral hepatitis. Ann Intern Med . 1969; 70 55-59
3 Dane D S, Cameron C H, Briggs M. Virus-like particles in the serum of patients with Australia-antigen associated hepatitis. Lancet . 1970; 1 695-698
4 Summers J, Mason W S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell . 1982; 29 403-415
5 Beasley R P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer . 1988; 61 1942-1956
6 Szmuness W, Stevens C E, Harley E J. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med . 1980; 303 833-841
7 Tuttleman J S, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell . 1986; 47 451-460
8 Zhu Y T, Yamamoto J, Cullen J. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol . 2001; 75 311-322
9 Chu C J, Lok A SF. Clinical significance of hepatitis B virus genotypes. Hepatology . 2002; 35 922-929
10 Brunetto M RS, Schodel M, Will F. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol . 1989; 21 151-154
11 Carman W F, Hadziyannis S, McGarvey M J. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet . 1989; 2 588-591
12 Funk M L, Rosenberg D M, Lok A S. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat . 2002; 9 52-61
13 Lindh M, Andersson A S, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J Infect Dis . 1997; 175 1285-1293
14 Rehermann B, Fowler P, Sidney J. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med . 1995; 181 1047-1058
15 Rehermann B, Lau D, Hoofnagle J H. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest . 1996; 97 1655-1665
16 Guidotti L G, Chisari F V. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol . 1996; 8 478-483
17 Chang M H, Chen C J, Lai M S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med . 1997; 336 1855-1859
18 Michalak T I, Pasquinelli C, Guilhot S. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest . 1994; 93 230-239
19 Fattovich G, Giustina G, Realdi G. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology . 1997; 26 1338-1342
20 de Jongh E F, Janssen H L, de Man A R. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology . 1992; 103 1630-1635
21 Yang H I, Lu S N, Liaw Y F. Taiwan Community-Based Cancer Screening Project. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med . 2002; 347 168-174
22 Lok A S, McMahon B J, and AASLD Practice Guidelines Committee. Chronic hepatitis B. Hepatology . 2001; 34 1225-1241